High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention

Mette Bjerre; Sune H. Pedersen; Rasmus Møgelvang; Søren Lindberg; Jan S Jensen; Søren Galatius; Allan Flyvbjerg

doi:10.1177/2047487313487083

High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention

Mette Bjerre, Sune H. Pedersen, Rasmus Møgelvang, Søren Lindberg, Jan S Jensen, Søren Galatius, Allan Flyvbjerg

21 Citations (Scopus)

Abstract

Background: Osteopontin (OPN), a multifunctional glycoprotein, has recently been found to be an important player in cardiovascular diseases and to be implicated in a variety of acute as well as chronic inflammatory processes, including atherosclerosis. This study investigates the association between plasma OPN at admission and the long-term outcome in patients with ST segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Methods: We included a total of 730 consecutive STEMI patients admitted to a single high-volume invasive heart centre between September 2006 and December 2008. Plasma OPNand high sensitivity C-reactive protein (hsCRP) were measured. Results: The median follow-up time was 27 months (interquartile range: 22-33) and endpoints were all-cause mortality, re-infarction and heart failure. Even when adjusted for all baseline variables, increasing OPN was independently associated with increased all-cause mortality, and the combined endpoint, a linear increase in OPN of 10 mg/l, was associated with a hazard ratio (HR) of 1.05 (95% confidence interval (CI): 1.02-1.08; p=0.002) for all-cause mortality and HR 1.03 (95%CI: 1.01-1.05; p=0.047) for the combined endpoint. Importantly, OPN interacted with the predictive power of hsCRP, and the combination of high OPN levels and high hsCRP levels (3 mg/l) were significantly associated with increased risk of allcause mortality (HR: 2.32; CI: 1.51-3.58; p0.001), re-infarction (HR: 2.19; CI: 1.22-3.93; p=0.006), heart failure (HR: 1.84; CI: 1.08-3.13; p=0.025) and the combined endpoint (HR: 2.08; CI: 1.53-2.84; p0.001). Conclusions: In conclusion, a high OPN level, especially in combination with a high hsCRP level, was associated with poor long-term outcome in STEMI patients treated with pPCI.

Original language	English
Journal	European Journal of Preventive Cardiology
Volume	20
Issue number	6
Pages (from-to)	922-929
Number of pages	8
ISSN	2047-4873
DOIs	https://doi.org/10.1177/2047487313487083
Publication status	Published - Dec 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/2047487313487083

https://academic.oup.com/eurjpc/article-pdf/20/6/922/34290382/eurjpc0922.pdf

Cite this

@article{2884efa4c01d479da0e8536272978a27,

title = "High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention",

abstract = "Background: Osteopontin (OPN), a multifunctional glycoprotein, has recently been found to be an important player in cardiovascular diseases and to be implicated in a variety of acute as well as chronic inflammatory processes, including atherosclerosis. This study investigates the association between plasma OPN at admission and the long-term outcome in patients with ST segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Methods: We included a total of 730 consecutive STEMI patients admitted to a single high-volume invasive heart centre between September 2006 and December 2008. Plasma OPNand high sensitivity C-reactive protein (hsCRP) were measured. Results: The median follow-up time was 27 months (interquartile range: 22-33) and endpoints were all-cause mortality, re-infarction and heart failure. Even when adjusted for all baseline variables, increasing OPN was independently associated with increased all-cause mortality, and the combined endpoint, a linear increase in OPN of 10 mg/l, was associated with a hazard ratio (HR) of 1.05 (95% confidence interval (CI): 1.02-1.08; p=0.002) for all-cause mortality and HR 1.03 (95%CI: 1.01-1.05; p=0.047) for the combined endpoint. Importantly, OPN interacted with the predictive power of hsCRP, and the combination of high OPN levels and high hsCRP levels (3 mg/l) were significantly associated with increased risk of allcause mortality (HR: 2.32; CI: 1.51-3.58; p0.001), re-infarction (HR: 2.19; CI: 1.22-3.93; p=0.006), heart failure (HR: 1.84; CI: 1.08-3.13; p=0.025) and the combined endpoint (HR: 2.08; CI: 1.53-2.84; p0.001). Conclusions: In conclusion, a high OPN level, especially in combination with a high hsCRP level, was associated with poor long-term outcome in STEMI patients treated with pPCI.",

author = "Mette Bjerre and Pedersen, {Sune H.} and Rasmus M{\o}gelvang and S{\o}ren Lindberg and Jensen, {Jan S} and S{\o}ren Galatius and Allan Flyvbjerg",

year = "2013",

month = dec,

doi = "10.1177/2047487313487083",

language = "English",

volume = "20",

pages = "922--929",

journal = "European Journal of Preventive Cardiology",

issn = "2047-4873",

publisher = "SAGE Publications",

number = "6",

}

TY - JOUR

T1 - High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention

AU - Bjerre, Mette

AU - Pedersen, Sune H.

AU - Møgelvang, Rasmus

AU - Lindberg, Søren

AU - Jensen, Jan S

AU - Galatius, Søren

AU - Flyvbjerg, Allan

PY - 2013/12

Y1 - 2013/12

N2 - Background: Osteopontin (OPN), a multifunctional glycoprotein, has recently been found to be an important player in cardiovascular diseases and to be implicated in a variety of acute as well as chronic inflammatory processes, including atherosclerosis. This study investigates the association between plasma OPN at admission and the long-term outcome in patients with ST segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Methods: We included a total of 730 consecutive STEMI patients admitted to a single high-volume invasive heart centre between September 2006 and December 2008. Plasma OPNand high sensitivity C-reactive protein (hsCRP) were measured. Results: The median follow-up time was 27 months (interquartile range: 22-33) and endpoints were all-cause mortality, re-infarction and heart failure. Even when adjusted for all baseline variables, increasing OPN was independently associated with increased all-cause mortality, and the combined endpoint, a linear increase in OPN of 10 mg/l, was associated with a hazard ratio (HR) of 1.05 (95% confidence interval (CI): 1.02-1.08; p=0.002) for all-cause mortality and HR 1.03 (95%CI: 1.01-1.05; p=0.047) for the combined endpoint. Importantly, OPN interacted with the predictive power of hsCRP, and the combination of high OPN levels and high hsCRP levels (3 mg/l) were significantly associated with increased risk of allcause mortality (HR: 2.32; CI: 1.51-3.58; p0.001), re-infarction (HR: 2.19; CI: 1.22-3.93; p=0.006), heart failure (HR: 1.84; CI: 1.08-3.13; p=0.025) and the combined endpoint (HR: 2.08; CI: 1.53-2.84; p0.001). Conclusions: In conclusion, a high OPN level, especially in combination with a high hsCRP level, was associated with poor long-term outcome in STEMI patients treated with pPCI.

AB - Background: Osteopontin (OPN), a multifunctional glycoprotein, has recently been found to be an important player in cardiovascular diseases and to be implicated in a variety of acute as well as chronic inflammatory processes, including atherosclerosis. This study investigates the association between plasma OPN at admission and the long-term outcome in patients with ST segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Methods: We included a total of 730 consecutive STEMI patients admitted to a single high-volume invasive heart centre between September 2006 and December 2008. Plasma OPNand high sensitivity C-reactive protein (hsCRP) were measured. Results: The median follow-up time was 27 months (interquartile range: 22-33) and endpoints were all-cause mortality, re-infarction and heart failure. Even when adjusted for all baseline variables, increasing OPN was independently associated with increased all-cause mortality, and the combined endpoint, a linear increase in OPN of 10 mg/l, was associated with a hazard ratio (HR) of 1.05 (95% confidence interval (CI): 1.02-1.08; p=0.002) for all-cause mortality and HR 1.03 (95%CI: 1.01-1.05; p=0.047) for the combined endpoint. Importantly, OPN interacted with the predictive power of hsCRP, and the combination of high OPN levels and high hsCRP levels (3 mg/l) were significantly associated with increased risk of allcause mortality (HR: 2.32; CI: 1.51-3.58; p0.001), re-infarction (HR: 2.19; CI: 1.22-3.93; p=0.006), heart failure (HR: 1.84; CI: 1.08-3.13; p=0.025) and the combined endpoint (HR: 2.08; CI: 1.53-2.84; p0.001). Conclusions: In conclusion, a high OPN level, especially in combination with a high hsCRP level, was associated with poor long-term outcome in STEMI patients treated with pPCI.

U2 - 10.1177/2047487313487083

DO - 10.1177/2047487313487083

M3 - Journal article

C2 - 23613225

SN - 2047-4873

VL - 20

SP - 922

EP - 929

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

IS - 6

ER -

High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this